Cardiac disease in the dialysis patient: Good, better, best clinical practice

Blood Purification

Volumn 27, Issue 1, 2009, Pages 99-113

  Hampl, Hannelore ^a,c   Riedel, Eberhard ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c NONE   (Germany)

Author keywords

Anemia management; Cardiac antihypertensive medication; Hemodialysis; Intensive iron therapy; Reactive thrombocytosis; Regression of left ventricular hypertrophy

Indexed keywords

ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; FERROUS ION; HEMOGLOBIN;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; ERYTHROCYTE; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMODIALYSIS PATIENT; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTOSIS;

ANEMIA, IRON-DEFICIENCY; HEART DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; THROMBOCYTOSIS;

EID: 58849125262     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167017     Document Type: Conference Paper

References (54)

1. Schäfer GE, Kaltenbach M, Schoeppe W: Hemodynamic response to chronic anemia in renal failure. Contrib Nephrol 1984;41:428-432.
2. Hampl H, Schäfer GE, Kessel M: Hemodynamic state in severe chronic renal failure. Nephron 1985;39:102-111.
3. Hampl H, Paeprer H, Unger V, Fischer C, Resa I, Kessel M: Hemodynamic changes during hemodialysis, sequential ultrafiltration, and hemofiltration. Kidney Int Suppl 1980;10:S83-S88.
4. Schäfer GE, Schoeppe W: Störungen der Herz- Kreislauffunktion bei terminaler Niereninsuffizienz und ihre Veränderungen unter chronischer Hämodialyse; in von Dittrich P (ed): Aktuelle Probleme der Dialyseverfahren und der Niereninsuffizienz. Friedberg, Bindernagel, 1981.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre DE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2004-2031.
6. Parfrey PS: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-1615.
7. Nelson DL, Cox MM: Lehninger Principles of Biochemistry. Heidelberg, Berlin, Oxford, Spektrum Akademischer Verlag, 1994, p 472.
8. Siems W, Carluccio F, Grune T, Jakstadt M, Quast S, Hampl H, Sommerburg O: Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin Nephrol 2002;58(suppl 1):20-25.
9. Grune T, Sommerburg O, Siems W: Oxidative stress in anemia. Clin Nephrol 2000;53(suppl 1):18-22.
10. Siems W, Sommerburg O, Grune T: Erythrocyte free radical and energy metabolism. Clin Nephrol 2000;53(suppl):9-17.
11. Hampl H, Berweck S, Ludat K, Fischer HC, Hertel J: How can hemodialysis-associated hypotension and dialysis-induced symptoms be explained and controlled - particularly in diabetic and arteriosclerotic patients? Clin Nephrol 2000;53(suppl 1):69-79.
12. Wanner C, Hörl WH: Carnitine abnormalities in patients with renal insufficiency: pathophysiological and therapeutic asoets. Nephron 1988;50:89-102.
13. Ahmed S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD: Multicenter trial of L -carnitine in maintenance hemodialysis patients. Kidney Int 1990;38:912-918.
14. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A: Intravenous L-carnitine increases plasma carnitine, reduces fatigue and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-1028.
15. Trovato GJ, Ginardi B, Di Marco V: Effects of L-carnitine on arrhythmias and angina during hemodialysis. J Mol Cell Cardiol 1983;15:25-30.
16. Trovato GM, Ginardi V, Di Marco V, Dell-Áira AE, Corsi M: Long-term L-carnitine treatment of chronic anemia in patients with end-stage renal failure. Curr Ther Res 1982;31:1042-1049.
17. Debska-Slizien A, Owczarzak A, Kunicka D: Plasma carnitine profile during chronic renal anemia treated with recombinant human erythropoietin. Int J Artif Organs 2003;26:33-38.
18. Labonia WD, Mortelli OH, Gimenez MI, Freuter PV, Morell OH: Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 1987;32:754-759.
19. Donatelli A, Terri C, Zummo G: Effects of L-carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res 1987;41:620-624.
20. Hampl H, Sternburg H, Berweck S, Lange D, Lorenz F, Pohle C, Riedel E, Gogoll L, Hennig L: Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol 2002;58:73-96.
21. Macdougall IC: Meeting the challenge of a new millennium: optimizing the use of human erythropoietin. Nephrol Dial Transplant 1998;13:23-27.
22. Ritos I: Three year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000;139:120-123.
23. Golper TA, Goral S, Becker BN: L-carnitine treatment of anemia. Am J Kidney Dis 2003;41:27-34.
24. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intercardiomyocytic fibrosis in uremic patients. Nephrol Dial Transplant 1990;5:39-44.
25. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992;42:1079-1085.
26. Amann K, Tyralla K: Cardiovascular changes in chronic renal failure. Pathogenesis and therapy. Clin Nephrol 2002;58(suppl 1):62-72.
27. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003;60(suppl 1):13-21.
28. London GM, Marchais SJ, Safar ME, Genest AF, Guerina AP, Metivier F, Chedi K, London AM: Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990;37:137-142.
29. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barrè PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-2031.
30. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio B, Zampi T, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
31. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass end geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
32. Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A: Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25:211-220.
33. Hampl H, Hennig L, Gogoll L, Riedel E: Complete anemia correction against cardiac events in uremic patients. J Am Soc Nephrol 2007;18:abstract SU-FC063.
34. Hampl H, Hennig L, Rosenberger C, Gogoll L, Riedel E, Scherhag A: Proven strategies to reduce cardiovascular mortality in hemodialysis patients. Blood Purif 2006;24:100-106.
35. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target hemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388.
36. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall LC, Tsakiris D, Burger HU, Scherhag A; for the Create Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2085.
37. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
38. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoeitin. N Engl J Med 1998;339:584-590.
39. Schloesser LL, Kipp MA, Wenzel FJ: Thrombocytosis in iron deficiency anemia. J Lab Clin Med 1965;66:107-114.
40. Gross S, Keefer V, Newman AJ: The platelets in iron deficiency anemia. Response in parenteral and oral iron. Pediatrics 1964;34:315-324.
41. Karpatkin S, Garg SK, Friedman MI: Role of iron as a regulator of thrombocytosis. Am J Med 1974;57:521.
42. Hart RG, Kanter MC: Hematologic disorders and ischemic stroke. A selective review. Stroke 1990;21:1111-1121.
43. Keung YK, Owen J: Iron deficiency and thrombosis:literature review. Clin Appl Thromb Hemost 2004;10:387-391.
44. Bilic E, Bilic E: Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia. J Pediatr Hematol Oncol 2003;25:675-676.
45. KDOQI: National Kidney Foundation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(suppl 3):S16-S85.
46. Hampl H, Hennig L, Gogoll L, Ahrens N: Hemoglobin targets in hemodialysis patients treated with very high dosages of erythropoiesis stimulating agents. Iron management. What is the problem? ASN meet, Philadelphia, 2008, in press.
47. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
48. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G: Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelets counts with erythropoietic activity and iron parameters. Eur J Haematol 1994;53:265-270.
49. McDonald TP, Cottrell MB, Clift RE, Cullen WC, Lin FK: High doses of recombinant erythropoietin stimulate platelet production in mice. Exp Hematol 1987;15:719-721.
50. Kalantar-Zadeh K, Streja E, Kopple J: High platelet count is associated with lower iron stores and higher ESA dose in hemodialysis patients: a possible explanation for hemoglobin survival paradox? ASN meeting, San Francisco, 2007.
51. Henry DH, Dahl NV, Auerbach M, Tchekmedyan S, Laufman LR: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
52. Fishbane S: Erythropoiesis-stimulating agent treatment with full anemia correction:a new perspective. Kidney Int 2008, E-pub ahead of print.
53. Hampl H, Ludat K, Paulitschke M: Correction of renal anemia with erythropoiesis-stimulating agents (ESA) to normal hematocrit (HCT) is not responsible for cardiovascular events (CV) in hemodialysis patients. ASN meeting, Philadelphia, 2008, in press.
54. Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, MacDougall IC, Wilson K: Iron and the anemia of chronic disease:a review and strategic recommendations. Curr Med Res Opin 2006;22:731-737.